Increased susceptibility to infectious disease is observed in persons with transfusion-dependent thalassemia and iron overload who experience increased exposure to pathogens and chronic immune stimulation. An abnormal low CD8 + T (LT8) immune phenotype defines a subgroup of patients. The CD8 + T cell immunophenotype is stable despite continued blood transfusion and is independent of age. CD8 + T cells, but not CD4 + T cells, were modulated during intravenous chelation with deferoxamine. Return to characteristic pretreatment levels of CD8 was observed in both the low and the normal groups, suggesting the possibility of a set point. Proliferative response to mitogens and antigens was increased by chelation. Because CD8 + T cells are important in immune response to infectious disease, these studies suggest that intrinsic CD8 + T cell subset differences may be a critical factor in determining susceptibility to infection independent of transfusional iron overload or alloantigen exposure.
Increased susceptibility to infectious disease is observed in persons with transfusion-dependent thalassemia and iron overload who experience increased exposure to pathogens and chronic immune stimulation. An abnormal low CD8 + T (LT8) immune phenotype defines a subgroup of patients. The CD8 + T cell immunophenotype is stable despite continued blood transfusion and is independent of age. CD8 + T cells, but not CD4 + T cells, were modulated during intravenous chelation with deferoxamine. Return to characteristic pretreatment levels of CD8 was observed in both the low and the normal groups, suggesting the possibility of a set point. Proliferative response to mitogens and antigens was increased by chelation. Because CD8 + T cells are important in immune response to infectious disease, these studies suggest that intrinsic CD8 + T cell subset differences may be a critical factor in determining susceptibility to infection independent of transfusional iron overload or alloantigen exposure.
Although iron is an essential micronutrient for immune response and specific effects have been described suggesting that iron may be a cofactor in the regulation of immune function, the mechanism(s) of action remains unclear [1] [2] [3] . Immune response is likely affected by iron at several levels. Iron has specific effects on both the adaptive and the innate immune systems [3] [4] [5] . Iron deficiency prevents the development and expression of cytotoxic effector T lymphocyte function [6] and is associated with reduced phagocytic activity toward some fungi, such as Candida albicans [7] . Conversely, excess iron promotes the formation of intracellular free radicals, which can cause oxidative damage [8] . Iron may favor the growth of intracellular pathogens by reducing production of key cytokines and by inhibiting phagocytic function [9] . Experimental iron overload also affects the balance between helper and cytotoxic T cells and impairs proliferative responses [10] . Iron may also promote the growth of hepatitis C virus [11] .
The two human settings in which the effect of iron on immune response can be most readily studied are transfusional iron overload [12] and hereditary hemochromatosis (HH) [13] . Transfusional iron overload occurs in conditions of chronic anemia, such as sickle cell anemia, aplastic anemia, and thalassemia, which require frequent blood transfusions. Thalassemia (Cooley's anemia) is a congenital hemolytic anemia associated with reduced or absent synthesis of b-globin chains caused by the inheritance of any of more than 100 b-globin gene mutations [14, 15] . Hypertransfusion therapy is used to maintain nearly normal hemoglobin levels and partially suppresses the increased, but ineffective, erythropoiesis [16] . Unfortunately, red blood cell transfusions are associated with alloimmunization, risk of exposure to infectious pathogens, and the accumulation of iron. Since there is no specific physiologic means of excreting iron, iron acquired from breakdown of transfused erythrocytes is retained [17, 18] , leading to poor growth, delayed puberty, diabetes mellitus, hepatic fibrosis, cardiac dysrhythmia, and eventually death [18] [19] [20] .
Removal of excess iron via chelation therapy is critical for protection against development of the diseases caused by iron toxicity [21] . The only currently approved chelating agent in the United States is deferoxamine (DFO), a naturally occurring bacterial siderophore. Chelation therapy is administered by prolonged subcutaneous infusions of DFO over 8-12 h, 5-7 days a week, while the patient sleeps. It is cumbersome and difficult for some parents and for children, adolescents, and adult patients; therefore, chelation is often used erratically and leads to iron accumulation, high serum ferritin levels, and eventually liver fibrosis. Significant immunologic abnormalities have been observed in thalassemia in relationship to the number of lifetime transfusions and iron overload [22, 23] .
Genetic control of iron uptake and metabolism was recently revealed through the discovery of the gene for HH, an autosomal recessive disorder of increased gastrointestinal iron uptake [24] . Evidence suggests that the normal gene product of HFE, a nonclassical gene of the major histocompatibility complex (MHC) homologous to MHC class I, regulates the me-tabolism and distribution of iron by affecting the binding of transferrin-bound iron to the transferrin receptor (Trfr) [25] . The normal gene product forms a stable complex with Trfr, which decreases its affinity for transferrin, whereas the C282Y mutation, one of two mutations currently identified in HH, prevents expression of the mutant protein on the cell surface. For reasons that are unclear, cells of the monocyte macrophage system are iron deficient in HH, while increased gastrointestinal uptake leads to iron overload of hepatic cells. The incidence of HH is closely linked with homozygosity for the C282Y mutation. However, the severity of disease expression, predominantly liver damage due to high iron stores, varies and is not directly associated with either gene mutation [26] [27] [28] [29] . Recent studies indicate that the T cell phenotype may be a marker for the outcome of altered iron metabolism in HH. Abnormally low numbers of CD8 ϩ lymphocytes in the peripheral circulation have been observed in association with high iron stores in a subgroup of persons with HH who also exhibit a shortened period to rebound of iron overload after therapeutic phlebotomy [29, 30] .
Since chronic blood transfusion also carries a cumulative risk of allosensitization and infection, analysis of potential causal relationships and mechanistic interactions between iron overload and the immune response requires extensive study at several levels. Recent findings implicating possible linkage of immune response genes to genetic control of iron metabolism provide a new basis for such studies. We recently obtained evidence suggesting that two subgroups of thalassemia patients can be distinguished according to their CD8 ϩ T lymphocyte percentage. A low CD8 T cell phenotype (LT8) appears to define an abnormal subtype in about one-third of thalassemia patients; the rest have CD8 ϩ T cells within the normal range. Here we report results of studies in which we assessed the influence of age on the CD8 ϩ T cell levels and the effect of therapeutic intravenous (iv) chelation on CD8 ϩ and CD4 ϩ T cell subsets in persons with or without the LT8 phenotype. We also assessed immune function and found that response to mitogens and antigens was reduced in thalassemia patients and improved after chelation. These studies support the suggestion that the CD8 ϩ T lymphocyte level may operate around an innate set point and that the deviation may affect one's susceptibility to infection [31] . The data also suggest that LT8 may be a disease-modifying factor in thalassemia analogous to its putative role in HH, where a relationship to progressive liver disease has been described [32] .
Methods
Patient population. The patients studied had homozygous bthalassemia and were followed regularly at the New York Presbyterian Hospital-Weill Medical College of Cornell University. Most (n p 42) are defined as having thalassemia major on the basis of transfusion dependence; those not requiring transfusion support are defined as having thalassemia intermedia (n p 4).
These patients are seen regularly for transfusion and/or comprehensive care visits. Most are of Italian (65%) or Greek (25%) extraction; the rest are of Asian/Indian ethnic ancestry. The patients are of both sexes and range in age from 2 to 148 years. In general, the patients are asymptomatic, although many, especially those у15 years of age, have varying degrees of underlying cardiac, endocrine, or liver disease due to iron overload.
Chelation protocol. Intravenous chelation with DFO was done in our NIH Children's Clinical Research Center. Thalassemia patients were infused (DFO at 60-120 mg/kg iv) over 8 h each night for 6 days.
Immunophenotyping.
Flow cytometry was performed on freshly isolated mononuclear cells from the peripheral blood of patients with thalassemia and adult controls. In previous studies, conventional whole blood methodology with a red cell lysis step yielded a lymphocyte gate with an unacceptably reduced purity due to persistent red cell contamination. Accordingly, ficoll-hypaque density gradient technique was used to collect mononuclear cells. Staining was done by standard techniques, and all samples were fixed [33, 34] . Cells were analyzed by flow cytometry employing dual fluorescence with a FACScalibur equipped with an argon laser (Becton Dickinson, Mountain View, CA), and Cell Quest or Simulset software (Becton Dickinson). The lymphocyte gating region was established for each specimen by fluorescence backgating with simultaneous detection of CD45 and CD14. Lymphocyte purity was 190% for all specimens. Data were obtained as percent positive and corrected for gate purity, and absolute counts were derived from the complete blood count and differential. Monoclonal antibodies used in this study included those defining CD3, CD4, CD8, and CD19 (Becton Dickinson). The immunology laboratory is fully certified through the NIH DAIDS proficiency program.
Lymphocyte proliferative response. Lymphocyte proliferative responses were assessed by microtiter assay [34] . In brief, mononuclear cells were isolated by density gradient technique over ficollhypaque and centrifuged for 30 min at 20ЊC at 1200 rpm (model T6000; Sorvall, Norwalk, CT). The mononuclear cell layer was collected and washed three times in Hanks' balanced salt solution. Cells were resuspended in RPMI 1640 with HEPES buffer, penicillin (40 IU/mL), streptomycin (40 mg/mL), L-glutamine (23 mg/ mL), and 10% pooled normal human serum. Lymphocytes were counted by light microscopy using a hemocytometer and plated at in triplicate in round-bottomed microtiter plates ( 4 4 5 ϫ 10 5 ϫ 10 lymphocytes/well) with multiple dilutions of each activator. Mitogens included phytohemagglutinin A (PHA; Difco, Detroit), pokeweed mitogen (PWM), and C. albicans antigen [34] . Mononuclear cells were incubated at 37ЊC for 4-5 days, then labeled with 0.04 mCi per well of [C 14 ]thymidine for 20 h, harvested by aspiration onto a filtermat, and finally counted in a b-plate scintillation counter (Wallac, Turku, Finland). Data were evaluated as mean triplicate responses to a range of concentrations of activators by comparison with responses in the absence of activation.
Results
Immunophenotypes in transfusional iron overload. Transfusion is life saving in thalassemia major but produces a very serious progressive iron overload that is only partially amelio- rated by regular chelation therapy. Iron overload develops over time in all transfusion-dependent thalassemia patients as measured by an increase in serum ferritin and related clinical changes such as cardiac toxicity and liver fibrosis. The latter become evident in the second to third decades of life. However, the degree of iron overload among patients is not strictly related to transfusion. In part, variability can be attributed to uneven compliance with the infusion of DFO, but this does not appear to be the sole reason. Our studies of iron excretion in response to cycles of chelation therapy suggest that patients may have intrinsic differences in the regulation of iron balance. Studies in HH have suggested that the CD8 T lymphocyte number is intrinsic to a subgroup of patients and is a marker for more aggressive iron accumulation. Since HH patients are treated by phlebotomy rather than by chelation therapy, we first looked at the CD8 ϩ T cell percentage and number in a small group of thalassasemics !3 years old who had begun regular transfusions but not yet received chelation therapy. As reported [35] , some of these children had low numbers and percentages of CD8 ϩ T cells in comparison with other patients and age-matched controls. This was associated with an increased CD4/CD8 ratio but no difference in CD4 ϩ T cells. We have extended this analysis to 46 thalassemia patients using standardized methodology [31] . The patients were studied longitudinally over a mean of 3 years (range, 2-6). CD8 ϩ T lymphocyte percentages were averaged to obtain a single overall representative level for each patient. Low CD8 ϩ T cell (LT8 ϩ ) immunophenotype was defined as р20% CD8 ϩ T cells. Levels 120% are normal (LT8 Ϫ ). About one-third of the patients were classified as LT8 ϩ [31] . Stability of the CD8 ϩ T cell level was evaluated by examination of variation over time for individual patients. Levels were remarkably constant in most cases, and variation was often !5%. Figure 1 
compares 4 representative LT8
ϩ patients with 4 LT8 Ϫ patients. We observed a remarkable stability of the CD8 ϩ T cell level in each patient over 4 years despite continuing biweekly blood transfusions. We then looked for agerelated changes. Because thalassemia patients are transfused every 2 weeks, are exposed to allogeneic stimulation, and have an increasing iron burden, it seemed logical that CD8 level might show age-related changes. We examined this possibility in the whole study group using individual exact age in 1999 and individual average CD8 level as full cross-sectional data. Figure 2 shows all 15 LT8 ϩ patients ordered by age with the corresponding CD8 value for each in the same vertical plane. Among the LT8 ϩ patients (age range, 8-48 years), the level of CD8 ϩ T cells showed only a very slight drop of about 3% over about four decades. Of interest, as shown in figure 3 , for 31 thalassemia patients with normal phenotype (LT8 Ϫ ) (age range, 2-42 years), the percentage of CD8 ϩ T cells showed a very slight increase (∼3%). These changes were not statistically significant.
Since changes in the two major subsets of CD3 ϩ T lymphocytes, CD4 and CD8, are usually interrelated and compensatory, we also looked for differences in relative CD4 level. We found no significant difference when LT8 ϩ patients were compared with LT8 Ϫ patients. Representative data are shown in figure 4 for 10 representative LT8 ϩ and 10 LT8 Ϫ patients. As shown, the difference between the two phenotypes was highly significant for CD8 (P ! .001) but not for the corresponding CD4 ϩ T cell levels.
Effect of therapeutic chelation in vivo on immunophenotype.
DFO, the only currently approved Food and Drug Administration iron chelator, is a naturally occurring trihydroxamic acid derived from Streptomyces pilosis. It has high affinity for iron under physiologic conditions and a lower affinity for trace metals. Since DFO is poorly absorbed from the gastrointestinal tract and is cleared relatively rapidly from the blood, it must be infused slowly, usually by subcutaneous administration. Most patients become severely iron overloaded over time, in part as a result of uneven compliance with this difficult regimen. All of the patients studied had increased serum ferritin levels (mean, 1707 ng/mL), an indication of excess body iron. Although a low CD8 ϩ T cell phenotype appears to correlate with an increased rate of iron loading in HH, this was not seen. Thus, the mean serum ferritin in the LT8 ϩ patients was ng/mL compared with in the LT8 Ϫ 1235 ‫ע‬ 872 1908 ‫ע‬ 1500 patients. Other histopathologic markers of iron overload measured in a small subset of patients did not reveal differences between those with and without the low CD8 phenotype. Metabolic iron studies involving iv administration of DFO provided an opportunity to evaluate the effect of iron chelation on the immune system under controlled conditions.
The immunophenotype was evaluated during intensive high dose iv chelation therapy in 19 iron-overloaded patients. The patients received 120 mg/kg infusions overnight for 6 nights. Initially we looked at the group as a whole for changes in lymphocyte subsets in response to chelation. Of the 19 patients, 11 (58%) showed a marked drop in CD8 ϩ T cells over the course of chelation, while 5 showed little or no change, and 1 had an increase in CD8 ϩ T cells. As shown in figure 5 , the difference between prechelation levels and the nadir (after 1-3 cycles) was significantly different for the group with the drop ( ). P p .03 Of this group, 4 had the low LT8 ϩ phenotype and 7 had the normal LT8 Ϫ immunophenotype. However, when we grouped all 19 patients by LT8 ϩ and LT8 Ϫ phenotype and compared the groups at each time point, the phenotypically defined groups remained constant and were significantly different from each other throughout as shown in table 1. The mean CD8 percentage was significantly lower in the LT8 ϩ group ( ) n p 10 compared with the LT8 Ϫ normal group ( ) at each time n p 9 point. Average time to follow-up time was 9 months.
Effect of therapeutic chelation in vivo on adaptive immune function in vitro. Several studies have suggested that thalassemia patients may have impaired immune responses in association with iron overload [36, 37] . We evaluated proliferative responses to PHA, a T cell-dependent mitogen, to PWM, a T cell-dependent B cell activator and to C. albicans antigen in a standard microtiter assay using isolated mononuclear cells. The response to PHA was significantly reduced in 17 thalassemia patients ( cpm) compared with 30 controls 14,547 ‫ע‬ 6605 ( cpm; ) studied in parallel. The response 24,946 ‫ע‬ 5020 P ! .001 to PWM was cpm in patients compared with 6004 ‫ע‬ 2637 in controls (
). The response to C. albicans 8853 ‫ע‬ 3984 P p .04 in 26 patients was , which was also reduced com-5256 ‫ע‬ 5201 pared with controls, ( ). The effect of DFO 8456 ‫ע‬ 4923 P p .03 chelation in response to C. albicans was examined in a subgroup of 6 patients after 1 or 2 cycles of chelation ( figure 6 ). There was a significant increase in the response to this antigen ( ). Response to mitogens was also increased. Thus, P p .001 response to antigen may be enhanced by iron chelation.
Discussion
Certain metals appear to have both concentration-dependent immunomodulatory and immunotoxic effects at pharmacologic concentrations [38] [39] [40] . Some are of interest as potential immune adjuvants [41] . Essential trace elements obtained from the diet, including iron, zinc, copper, selenium, and chromium, have critical effects on immune response at physiologic con- centration, such that altered levels may compromise responses to infection through regulation of specific immune mechanisms [42] [43] [44] . Iron is unique among metals because of its central role in oxygen transport. However, excess iron also promotes microbial growth and can suppress immune function. Iron-dependent gene regulation has been observed in bacteria [45] , and mechanisms controlling iron uptake from the environment have been identified [46] . In contrast, control of iron intake in higher organisms has not been clarified. The discovery of the gene HFE, which regulates the metabolism and distribution of iron by affecting the binding of transferrin-bound iron to Trfr, has been a major breakthrough by showing that the molecular basis of HH can be attributed to homozygous inheritance of the C282Y mutation of HFE [24, 25] . HFE is analogous to MHC class I molecules in sequence and three-dimensional structure and is also noncovalently associated with b2-microglobulin (b2-m). However, the HFE protein does not bind peptides or appear to interact with T cells [47] . The normal gene product of HFE appears to reduce iron uptake by interfering with the binding affinity of transferrin to the transferrin receptor and by decreasing receptor cycling [48] . The significance of the physical association of HFE with b2-m and consequently with MHC class I is unclear. Excess iron has been observed in association with loss of CD8 ϩ T lymphocytes in the b2-m knockout mouse. CD8 ϩ T cells are also reduced in a subgroup of HH patients who show an increased rate of iron loading [49] . Cell surface expression of the HFE protein has been shown on many cells, including monocytes and macrophages, but has not been found on lymphocytes [50] . Thus, there is no clear relationship between the CD8 ϩ T cell level in HH and mutations in the HFE gene. However, up-regulation of the transferrin receptor leading to receptor-mediated uptake of iron is a crucial step in lymphocyte activation [51] . Of interest, new studies in compound mutant mice lacking both Hfe and b2-m show that more iron is deposited in various tissues than is observed in mice with either single mutation, suggesting there is another b2m-linked mutation involved in iron regulation. Levy et al. [52] speculated that this may be another atypical MHC class I molecule or that the compromised immune system of the b2-m mouse may exacerbate the iron loading phenotype of the Hfe Ϫ / Ϫ mouse by an indirect mechanism that is not yet understood.
Iron overload in thalassemia is secondary to treatment for anemia and leads to an adaptive response that may be conditioned by the presence of heterozygosity for HFE mutations. Furthermore, thalassemia patients are exposed to potential bloodborne pathogens such as hepatitis C virus (HCV), hepatitis G virus, B19 parvovirus, cytomegalovirus, and human immunodeficiency virus (HIV) types 1 and 2 [53] [54] [55] [56] . The significance of iron overload for immune response in thalassemia is indirectly supported by reports of increased bacterial infections [57] [58] [59] . Iron overload promotes progression of HCV infection and inhibits response to treatment with interferon-a [60] [61] [62] . Thalassemia patients without HCV infection also show increased risk of hepatoma, which appears to be promoted by chronic exposure to high levels of iron [63] . Studies suggest that DFO may reduce progression of HIV infection and that increasing serum ferritin is associated with progression in thalassemia [64, 65] . Thalassemia patients are generally splenectomized in an effort to maintain hemoglobin levels without increasing transfusion requirements and have a potentially increased risk of infection that is managed by pneumococcal immunization and antibiotic prophylaxis [66] .
Studies of the immune system in thalassemia suggest chronic activation in association with allogeneic stimulation and iron overload and transient effects of trace element removal by chelation [67] [68] [69] [70] [71] [72] . However, there are no repetitious episodes of infections that are characteristic of intrinsic immune deficiency. While there is no evidence for any preexisting intrinsic immune deficiency in thalassemia, a recent investigation suggested there is an innate defect in monocyte/macrophage phagocytosis of erythrocytes in HH [73] .
We recently found that the low CD8 immunophenotype is associated with the absence of a second mutation in the HFE gene, H63D, and also with susceptibility to hepatitis C [31] . We also observed that the presence of the H63D mutation was associated with a lowered frequency of HCV infection among ). P p .001 thalassemia patients with equivalent transfusion exposure. Here, we present evidence that the low CD8 immunophenotype is not a consequence of the host's age and that this phenotype is reestablished after the perturbation caused by iv DFO administration. We also observed that chelation affected proliferative responses to mitogens to the antigen C. albicans. Since iron is both essential for oxygenation and potentially toxic, multiple mechanisms may have evolved to provide a means of maintaining balance within the hematopoietic system. Transfusional iron overload provides a unique model in which genes controlling iron metabolism can be observed in interaction with the immune system.
